Contributions
Abstract: P1134
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Objective: To determine if oligoclonal immunoglobulin bands (OCB) status changes during longitudinal follow up and which factors influences that in treatment naïve and treated MS patients.
Background: Nordic MS population carries OCBs in CSF in 90-95% of cases. Qualitative and quantitative changes of OCBs in CSF might occur due to immunomodulatory treatment. Oligolonal bands in CSF are risk factor of CIS conversion to MS.
Methods: We used data from clinically definite MS patients with known OCB-status registered in the Swedish MS register. Date of birth, sex, date of first relapse, diagnosis date and dates for lumbar punctures, data on first and second line immunomodulatory treatment was collected. Multivariate logistic regression model was used to investigate the influence of time length between first relapse and lumbar puncture dates for risk to carry OCBs in CSF; the same method was used to evaluate influence of duration of first and second line disease modifying treatment for risk to OCB status changes from OCB+ to OCB-.
Results: 4,728 relapsing remitting (RR) patients were included. Overall, 475 (10%) were OCB negative. Cohort included 72.9% females. Median EDSS was 2.5. Statistics is still ongoing to meet the project objectives.
Conclusions: This study reveals factors relevant for OCB status changes during follow up time in treatment naïve and treated MS patients.
Disclosure: This study was supported by Biogen. VDK and AM report no conflicts of interest. JH received honoraria for serving on advisory boards for Biogen, Sanofi-Genzyme and Novartis and speaker"s fees from Biogen, Merck-Serono, Bayer-Schering, Teva and Sanofi-Genzyme. He has served as P.I. for projects sponsored by, or received unrestricted research support from, Biogen, Merck-Serono, TEVA, Novartis, Sanofi-Genzym
Abstract: P1134
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Objective: To determine if oligoclonal immunoglobulin bands (OCB) status changes during longitudinal follow up and which factors influences that in treatment naïve and treated MS patients.
Background: Nordic MS population carries OCBs in CSF in 90-95% of cases. Qualitative and quantitative changes of OCBs in CSF might occur due to immunomodulatory treatment. Oligolonal bands in CSF are risk factor of CIS conversion to MS.
Methods: We used data from clinically definite MS patients with known OCB-status registered in the Swedish MS register. Date of birth, sex, date of first relapse, diagnosis date and dates for lumbar punctures, data on first and second line immunomodulatory treatment was collected. Multivariate logistic regression model was used to investigate the influence of time length between first relapse and lumbar puncture dates for risk to carry OCBs in CSF; the same method was used to evaluate influence of duration of first and second line disease modifying treatment for risk to OCB status changes from OCB+ to OCB-.
Results: 4,728 relapsing remitting (RR) patients were included. Overall, 475 (10%) were OCB negative. Cohort included 72.9% females. Median EDSS was 2.5. Statistics is still ongoing to meet the project objectives.
Conclusions: This study reveals factors relevant for OCB status changes during follow up time in treatment naïve and treated MS patients.
Disclosure: This study was supported by Biogen. VDK and AM report no conflicts of interest. JH received honoraria for serving on advisory boards for Biogen, Sanofi-Genzyme and Novartis and speaker"s fees from Biogen, Merck-Serono, Bayer-Schering, Teva and Sanofi-Genzyme. He has served as P.I. for projects sponsored by, or received unrestricted research support from, Biogen, Merck-Serono, TEVA, Novartis, Sanofi-Genzym